The short version of melanocortin receptors fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-29 and is reviewed periodically as new material appears.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic cyclic heptapeptide | Alpha-MSH analogue containing a D-phenylalanine residue |
| Molecular formula | C50H69N15O9 | Average molecular mass approximately 1024.2 g/mol |
| Appearance | White to off-white lyophilised powder | Normally supplied as a freeze-dried solid in a sealed vial |
| Solubility | Freely soluble in water and polar solvents | Dissolves readily in aqueous buffers and in alcohol-water mixtures |
| Receptor targets | MC1R, MC3R, MC4R, MC5R | Acts as a non-selective melanocortin receptor agonist |
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
=== Economic impact === In addition to its health impacts, obesity can lead to many problems, including disadvantages in employment and increased business costs. Research estimated the medical costs attributable to obesity in the US in 2005 at $190.2 billion or 20.6% of all medical expenditures, while the cost of obesity in Canada was estimated at CA$2 billion in 1997 (2.4% of total health costs). The total annual direct cost of overweight and obesity in Australia in 2005 was A$21 billion. Overweight and obese Australians also received A$35.6 billion in government subsidies. The estimated range for annual expenditures on diet products is $40 billion to $100 billion in the US alone. The Lancet Commission on Obesity in 2019 called for a global treaty—modelled on the WHO Framework Convention on Tobacco Control—committing countries to address obesity and undernutrition, explicitly excluding the food industry from policy development. They estimated the global cost of obesity at $2 trillion a year, about or 2.8% of world GDP. Obesity-prevention programs demonstrably reduce the cost of treating obesity-related disease. However, the longer people live, the more medical costs they incur. Analysis therefore concludes that reducing obesity may improve the public's health, but that it is unlikely to reduce health spending overall. Globally, certain countries have implemented sin taxes (such as a sugary drink tax) to curb dietary and consumer habits and to offset economic costs.
The 2nd Belarusian Partisan Brigade was a Soviet Partisan formation that operated in the Nazi-occupied territories of the Byelorussian SSR and other areas during World War 2. they primarily operated in the Mekhovsky, Gorodonsky, and Surazhsky Districts of the Vitebsk region. The Brigade was established twice; the first formation was disbanded in early 1943. Before being reconstituted, operations were to continue until the arrival of the Red Army.
=== Injections and implants === In 1933 or 1934, Schering introduced progesterone in oil solution as a medication by intramuscular injection under the brand name Proluton. This was the first pharmaceutical formulation of progesterone to be marketed for medical use. It was initially a corpus luteum extract, becoming pure synthesized progesterone only subsequently. A clinical study of the formulation was published in 1933. Multiple formulations of progesterone in oil solution for intramuscular injection, under the brand names Proluton, Progestin, and Gestone, were available by 1936. A parenteral route was used because oral progesterone had very low activity and was thought to be inactive. Progesterone was initially very expensive due to the large doses required. However, with the start of steroid manufacturing from diosgenin in the 1940s, costs greatly decreased. Subcutaneous pellet implants of progesterone were first studied in women in the late 1930s. They were the first long-acting progestogen formulation. Pellets were reported to be extruded out of the skin within a few weeks at high rates, even when implanted beneath the deep fascia, and also produced frequent inflammatory reactions at the site of implantation. In addition, they were absorbed too slowly and achieved unsatisfactorily low progesterone levels. Consequently, they were soon abandoned, in favor of other preparations such as aqueous suspensions.
In 1992, the Moscow government began planning a new area in central Moscow—the Moscow International Business Center—to create a zone, the first in Russia and Eastern Europe, to combine business activity, living space, and entertainment. Situated in the Presnensky District and located at the Third Ring, the Moscow City area is undergoing intensive development. The Moscow International Business Center (MIBC) is being constructed on the Krasnopresnenskaya embankment. The project occupies up to one square kilometer (250 acres). That area is the only location in downtown Moscow able to accommodate a project of such size. Most pre-existing buildings in that area are old factories and industrial complexes. Demonstrating the MIBC's scale, the Federation Tower, completed in 2016, is the second-tallest building in Europe. The project's broader plans include a water park and other recreational facilities; business, office, entertainment, and residential buildings; a transport network; and a new site for the Moscow government. Four new metro stations in the area have been built; two of these have opened, and two others are reserved for future metro lines crossing the MIBC. Additional stations were planned. In addition, a rail shuttle service is planned to directly connect the MIBC with the Sheremetyevo International Airport. Major thoroughfares through the MIBC are the Third Ring and Kutuzovsky Prospekt. Three metro stations were initially planned for the Filyovskaya Line. The Delovoi Tsentr station opened in 2005 and was renamed Vystavochnaya in 2009.
Sources: en.wikipedia.org
Raleigh is home to a wide variety of religious practitioners. The predominant religion in Raleigh is Christianity, with the largest numbers of adherents being Baptist (14.1%), Methodist (5.6%), and Roman Catholic (4.2%). Others include Presbyterianism (2.8%), Pentecostalism (1.7%), Anglicanism/Episcopalianism (1.2%), Lutheranism (0.6%), the Latter-Day Saints (0.7%), and other Christian denominations (10.2%) including the Eastern Orthodox, Oriental Orthodox, Jehovah's Witness, Christian Science, Christian Unitarianism, other Mainline Protestant groups, and non-denominational Christians. The Roman Catholic Diocese of Raleigh, the Episcopal Diocese of North Carolina, the Coptic Orthodox Diocese of South Carolina, North Carolina, and Kentucky, the North Carolina Annual Conference of the United Methodist Church, and the New Hope Presbytery of the Presbyterian Church (USA) are all headquartered in Raleigh. Other religions, including Hinduism, Buddhism, Baháʼí, Druze, Taoism, and Shintoism make up 1.31% of religious practitioners. Judaism (0.9%) and Islam (0.8%) are also practiced. In Wake County, 29% of the population are affiliated with the Southern Baptist Convention, 22% are affiliated with the Catholic Church, 17% are affiliated with the United Methodist Church, 6% are affiliated with the Presbyterian Church (USA), and 27% are religiously affiliated with other denominations, religions, or are not religiously affiliated.
=== Pneumococcal vaccine === From 1971 to 1985, Ammann was director of Pediatric Immunology and Clinical Research Center at UCSF. It was during this period that Ammann performed a series of clinical trials aimed at protecting children with sickle cell anemia and the elderly from pneumococcal infection, a bacterium that causes fatal infection. He and his colleagues were successful in creating the first U.S. Food and Drug Administration-approved vaccine effective against the bacteria; it granted individuals immunity against a life-threatening infection. Ammann's vaccine has since been expanded and its immunogenicity has been improved, increasing the effectiveness of the vaccine in young infants. This discovery has saved the lives of millions of individuals by preventing pneumococcal infection, particularly in children and the elderly.
Physical pharmacy is the branch of pharmacy that concentrates on the applications of physics and chemistry to the study of pharmacy. In other words, it is the study of the effects that dosage forms have on their environment by addressing issues at the molecular level. It emphasis on the physical characteristics and actions of the drug delivery system before the same is given to the patient. It forms the basis for design, manufacture, and distribution of drug products and serves as the foundation for the stable and proper use of medical drugs. It covers areas such as solubility, pharmacokinetics and drug delivery. Physical pharmacy serves as principles that guide the pharmaceutical developments. It also serves as a basis for the understanding of drug absorptions, distributions, metabolism, and eliminations that happen during the course of drug treatment.
Treatment of macrophages with lipopolysaccharide (LPS), a major component of the Gram-negative bacteria outer membrane, results in elevated O-GlcNAc in cellular and mouse models. During infection, cytosolic OGT was de-S-nitrosylated and activated. Suppressing O-GlcNAc with DON inhibited the O-GlcNAcylation and nuclear translocation of NF-κB, as well as downstream induction of inducible nitric oxide synthase and IL-1β production. DON treatment also improved cell survival during LPS treatment.
These complexes are often laid out in a similar fashion, and they can contain many different modules to perform a diverse set of chemical manipulations on the developing product. These peptides are often cyclic and can have highly complex cyclic structures, although linear nonribosomal peptides are also common. Since the system is closely related to the machinery for building fatty acids and polyketides, hybrid compounds are often found. The presence of oxazoles or thiazoles often indicates that the compound was synthesized in this fashion. Peptones are derived from animal milk or meat digested by proteolysis. In addition to containing small peptides, the resulting material includes fats, metals, salts, vitamins, and many other biological compounds. Peptones are used in nutrient media for growing bacteria and fungi. Peptide fragments refer to fragments of proteins that are used to identify or quantify the source protein. Often these are the products of enzymatic degradation performed in the laboratory on a controlled sample, but can also be forensic or paleontological samples that have been degraded by natural effects.
Sources: en.wikipedia.org
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.
No approved regulatory indication exists in major markets. An approval exists for a different peptide, afamelanotide, which is used for a rare photosensitivity disorder called erythropoietic protoporphyria. Melanotan-2 itself remains a research compound with no cleared clinical role.
Melanocortin-1 receptors on melanocytes are the receptor most closely linked to pigment production. The peptide is not selective, however, and also activates melanocortin-3, melanocortin-4, and melanocortin-5 receptors. That lack of selectivity is the usual explanation offered for both its range of observed effects and its off-target effects.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.